Publications

Detailed Information

Wine drinking and epithelial ovarian cancer risk: a meta-analysis

DC Field Value Language
dc.contributor.authorKim, Hee Seung-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorShouten, Leo J.-
dc.contributor.authorLarsson, Susanna C.-
dc.contributor.authorKim, Yong Beom-
dc.contributor.authorPark, Noh Hyun-
dc.contributor.authorKim, Seung Cheol-
dc.contributor.authorKang, Soon-Beom-
dc.contributor.authorSong, Yong Sang-
dc.contributor.authorJu, Woong-
dc.contributor.authorChung, Hyun Hoon-
dc.date.accessioned2012-06-05T00:15:19Z-
dc.date.available2012-06-05T00:15:19Z-
dc.date.issued2010-06-
dc.identifier.citationJOURNAL OF GYNECOLOGIC ONCOLOGY; Vol.21 2; 112-118ko_KR
dc.identifier.issn2005-0380-
dc.identifier.urihttps://hdl.handle.net/10371/76813-
dc.description.abstractObjective: Wine has been the focus in the prevention of epithelial ovarian cancer (EOC) development because resveratrol abundant in wine has anti-carcinogenic properties. However, epidemiologic results have been heterogenous in the chemopreventive effect of wine on the development of EOC. Thus, we performed a meta-analysis for comparing EOC risk between wine and never drinkers using previous related studies. Methods: After extensive search of the literature between January 1986 and December 2008, we analyzed 10 studies (3 cohort and 7 case control studies) with 135,871 women, who included 65,578 of wine and 70,293 of never drinkers. Results: In all studies, there was no significant difference in EOC risk between wine and never drinkers (odds ratio [OR], 1.13; 95% confidence interval [CI], 0.92 to 1.38; random effects). When we performed re-analysis according to the study design, 3 cohort and 7 case control studies showed that there were also no significant differences in EOC risk between wine and never drinkers, respectively (OR, 1.44 and 1.04; 95% CI, 0.74 and 2.82 and 0.88 to 1.22; random effects). In sub-analyses using 2 case-control studies, EOC risk was not different between former and never drinkers (OR, 1.12; 95% CI, 0.87 to 1.44; fixed effect), and between current and former drinkers (OR, 0.74; 95% CI, 0.41 to 1.34; random effects). Conclusion: Although resveratrol, abundantly found in wine, is a promising naturally occurring compound with chemopreventive properties on EOC in preclinical studies, this meta-analysis suggests the epiderniologic evidence shows no association between wine drinking and EOC risk.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPYko_KR
dc.subjectWineko_KR
dc.subjectResveratrolko_KR
dc.subjectEpithelial ovarian cancerko_KR
dc.titleWine drinking and epithelial ovarian cancer risk: a meta-analysisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김희승-
dc.contributor.AlternativeAuthor김재원-
dc.contributor.AlternativeAuthor정현훈-
dc.contributor.AlternativeAuthor김용범-
dc.contributor.AlternativeAuthor주웅-
dc.contributor.AlternativeAuthor박노현-
dc.contributor.AlternativeAuthor송용상-
dc.contributor.AlternativeAuthor김승철-
dc.contributor.AlternativeAuthor강순범-
dc.identifier.doi10.3802/jgo.2010.21.2.112-
dc.citation.journaltitleJOURNAL OF GYNECOLOGIC ONCOLOGY-
dc.description.citedreferenceKim K, 2009, J GYNECOL ONCOL, V20, P203, DOI 10.3802/jgo.2009.20.4.203-
dc.description.citedreferenceGoswami SK, 2009, CANCER LETT, V284, P1, DOI 10.1016/j.canlet.2009.01.041-
dc.description.citedreferenceBlagden S, 2009, CURR OPIN ONCOL, V21, P412, DOI 10.1097/CCO.0b013e32832eab1f-
dc.description.citedreferenceRaj MHG, 2008, GYNECOL ONCOL, V110, P432, DOI 10.1016/j.ygyno.2008.05.001-
dc.description.citedreferenceChang ET, 2008, NUTR CANCER, V60, P285, DOI 10.1080/01635580701733091-
dc.description.citedreferenceTworoger SS, 2008, CANCER, V112, P1169, DOI 10.1002/cncr.23275-
dc.description.citedreferencePark SY, 2007, CANCER LETT, V258, P63, DOI 10.1016/j.canlet.2007.08.011-
dc.description.citedreferenceKueck A, 2007, GYNECOL ONCOL, V107, P450, DOI 10.1016/j.ygyno.2007.07.065-
dc.description.citedreferenceGallus S, 2007, INT J CANCER, V121, P2578, DOI 10.1002/ijc.22967-
dc.description.citedreferenceCelik Y, 2007, CLIN NEUROL NEUROSUR, V109, P505, DOI 10.1016/j.clineuro.2007.02.011-
dc.description.citedreferenceChang ET, 2007, CANCER CAUSE CONTROL, V18, P91, DOI 10.1007/s10552-006-0083-x-
dc.description.citedreferencePeterson NB, 2006, INT J CANCER, V119, P2423, DOI 10.1002/ijc.22137-
dc.description.citedreferenceHeintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161-
dc.description.citedreferenceSankaranarayanan R, 2006, BEST PRACT RES CL OB, V20, P207, DOI 10.1016/j.bpobgyn.2005.10.007-
dc.description.citedreferenceGenkinger JM, 2006, BRIT J CANCER, V94, P757, DOI 10.1038/sj.bjc.6603020-
dc.description.citedreferenceTyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165-
dc.description.citedreferenceStopper H, 2005, MUTAT RES-FUND MOL M, V574, P139, DOI 10.1016/j.mrfmmm.2005.01.029-
dc.description.citedreferenceWietrzyk J, 2005, ANTICANCER RES, V25, P2357-
dc.description.citedreferenceLarsson SC, 2004, CANCER EPIDEM BIOMAR, V13, P1823-
dc.description.citedreferenceWebb PM, 2004, CANCER EPIDEM BIOMAR, V13, P592-
dc.description.citedreferenceLarsson SC, 2004, J NATL CANCER I, V96, P396, DOI 10.1093/jnci/djh061-
dc.description.citedreferenceSchouten LJ, 2004, CANCER CAUSE CONTROL, V15, P201-
dc.description.citedreferenceOpipari AW, 2004, CANCER RES, V64, P696-
dc.description.citedreferenceModugno F, 2003, OBSTET GYNECOL, V102, P1336, DOI 10.1016/S0029-7844(03)00949-9-
dc.description.citedreferenceHiggins JPT, 2003, BRIT MED J, V327, P557-
dc.description.citedreferenceOzols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153-
dc.description.citedreferenceGoodman MT, 2003, OBSTET GYNECOL, V101, P1221, DOI 10.1016/S0029-7844(03)00050-4-
dc.description.citedreferenceYang SH, 2003, INT J ONCOL, V22, P741-
dc.description.citedreferenceHO SM, 2003, REPROD BIOL ENDOCRIN, V1, P73-
dc.description.citedreferenceRimando AM, 2002, J AGR FOOD CHEM, V50, P3453, DOI 10.1021/jf0116855-
dc.description.citedreferencePotter GA, 2002, BRIT J CANCER, V86, P774, DOI 10.1038/sj/bjc/6600197-
dc.description.citedreferenceWolter F, 2002, J NUTR, V132, P298-
dc.description.citedreferenceSingletary KW, 2001, JAMA-J AM MED ASSOC, V286, P2143, DOI 10.1001/jama.286.17.2143-
dc.description.citedreferenceSterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8-
dc.description.citedreferenceTavani A, 2001, NUTR CANCER, V39, P29, DOI 10.1207/S15327914nc391_4-
dc.description.citedreferenceShin NH, 1998, BIOCHEM BIOPH RES CO, V243, P801-
dc.description.citedreferenceCooper GS, 1996, EPIDEMIOLOGY, V7, P624-
dc.description.citedreferenceLAVECCHIA C, 1992, J CLIN EPIDEMIOL, V45, P1025-
dc.description.citedreferenceGWINN ML, 1986, AM J EPIDEMIOL, V123, P759-
dc.description.citedreferenceROSENBERG L, 1982, LANCET, V1, P267-
dc.description.tc1-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share